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Objective: To investigate the impact of exacerbations in health-related quality of life (HRQL) 
of patients with COPD and to compare the effect of treatment of COPD exacerbations with 
moxifloxacin (400 mg/day for 5 days) and amoxicillin/clavulanate (500/125 mg 3 times a day 
for 10 days) on HRQL.
Methods: 229 outpatients with stable COPD (mean age 68.2 years; mean FEV1 % predicted 
49.3%) participated in a prospective, observational study of 2 years’ duration. The St George’s 
Respiratory Questionnaire (SGRQ) was completed at baseline and every 6 months thereafter.
Results: COPD exacerbations (mean 2.7 episodes/patient) occurred in 136 patients (124 patients 
received the study medications [amoxicillin/clavulanate 54, moxifloxacin 70]). Differences 
between baseline and the final visit were higher for moxifloxacin compared with amoxicillin/
clavulanate for total SGRQ score (-2.60 [13.1] vs 4.21 [16.2], P = 0.05) and “Symptoms” 
subscale (-5.64 [16.7] vs 8.27 [21], P = 0.02). The same findings were observed in patients 
with two or more exacerbations.
Conclusions: In COPD outpatients, treatment of exacerbations with moxifloxacin had a more 
favorable long-term effect on quality of life than amoxicillin/clavulanate.
Keywords: COPD, exacerbations, moxifloxacin, amoxicillin/clavulanate, quality of life, SGRQ
Introduction
Chronic obstructive pulmonary disease (COPD) affects a large number of subjects 
worldwide and is characterized by a progressively rising epidemiological, clinical 
and socio-economic impact.1,2 The objectives of treatment are to decrease the burden 
of the disease through relief of symptoms, improvement of exercise tolerance, and 
prevention and treatment of exacerbations. Patients with moderate to severe disease 
suffer an average of two episodes of acute exacerbation a year, leading to hospital 
admission in 10% of cases.3 Furthermore, an increased number of past exacerbations 
is one of the best predictors for the risk of future recurrent exacerbations and relapse 
after treatment.4,5
Infections are responsible for 75% of exacerbations of COPD.6 In Spain, empiric 
antibiotic treatment is prescribed in more than 90% of cases of respiratory exacerba-
tion of COPD, although microbiological analysis of sputum is only undertaken in 5% 
of patients.3,7,8 Penicillins, cephalosporins and macrolides are the most widely used 
antibiotics to treat exacerbation of chronic bronchitis and COPD in Spain, followed 
by quinolones.3 Appropriate antibiotic treatment is crucial since bacteriologic eradi-
cation is associated with longer infection-free intervals.9 Moxifloxacin is a fourth-
generation fluoroquinolone that has been shown to be effective against respiratory International Journal of COPD 2010:5 12
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pathogens, including atypicals and those resistant to most 
common antibiotics.10–12 Moxifloxacin has demonstrated 
better eradication13 and faster recovery of symptoms14–16 in 
exacerbations of chronic bronchitis and COPD compared 
with standard therapy, in particular, with macrolides. There-
fore, some guidelines recommend the use of moxifloxacin as 
first-line therapy in bacterial exacerbations in patients with 
moderate to severe COPD and in patients with mild COPD 
with risk factors.17
Exacerbations of COPD cause an important and perma-
nent impairment in the quality of life of these patients.18,19 
Different studies using both generic and disease-specific 
instruments have shown that health-related quality of life 
(HRQoL) is impaired in patients with severe COPD.20–22 
However, most of these studies have been carried out in 
patients controlled by specialists in the hospital setting. For 
this reason, it is important to assess the effect of exacerba-
tions on HRQoL of patients with less severe COPD visited 
in the primary care setting, where most COPD patients are 
attended.
The current study attempts to evaluate the impact of 
exacerbations on HRQoL and to investigate the effect of 
two antimicrobial treatments in modulating the impairment 
caused by exacerbations on the long-term evolution of health 
status. The study design and the impact of exacerbations 
on the whole population have been reported elsewhere.23,24 
The present article describes the effects of treatment of 
acute exacerbations with moxifloxacin versus amoxicillin/
clavulanate on changes of the St. George’s Respiratory Ques-
tionnaire (SGRQ). The assessment of changes of HRQoL 
in association with antibiotic treatment of exacerbations is 
a novel approach to explore the effectiveness of different 
antimicrobial regimens in patients with COPD.
Materials and methods
Design
The EVOCA study (Spanish acronym of EVOlución de la 
CAlidad de vida en pacientes con EPOC – Evolution of the 
quality of life in patients with COPD) was a prospective, 
observational, multicenter study of a cohort of patients with 
COPD followed in primary care over a 2-year period. The 
primary objective of the study was to assess the impact 
of exacerbations of COPD on the patients’ quality of life 
measured by the SGRQ and to determine whether there 
were differences between patients treated with moxifloxa-
cin and those treated with amoxicillin/clavulanate. Due to 
the lack of previous studies, the magnitude of changes in 
the SGRQ scores over a period of 2 years in patients with 
moderate COPD in primary care was unknown at the time 
of designing the study.23,24 Based on data of the only study 
available, 78 patients with severe COPD followed for one 
year were sufficient to detect significant differences in 
the SGRQ scores between patients with a higher or lower 
number of acute exacerbations than the median value.21 
Accordingly, a sample of 200 patients with COPD was 
considered adequate to observe any significant changes 
in quality of life related to the frequency of exacerbations 
over 2 years, considering losses of up to 20% and that the 
frequency of exacerbation in patients with moderate COPD 
visited in primary care could be lower than in the refer-
ence study.21 Approximately 30 family physicians working 
in different primary care centers throughout Spain were 
asked to recruit the first 10 patients who met the inclu-
sion criteria by nonprobabilistic sampling of consecutive 
cases. Patient enrolment took place between November 
2002 and July 2003. The study protocol was approved by 
the Spanish health authorities and all patients gave written 
informed consent.
study population
Eligible patients were adults over 40 years of age, smok-
ers or ex-smokers of at least 10 pack-years, with chronic 
bronchitis characterized by persistent cough and sputum 
production for 3 months per year for at least 2 consecu-
tive years, and stable COPD. Establishing the diagnosis of 
COPD required the observation of a non-reversible airflow 
obstruction characterized on post-bronchodilator forced 
spirometry by a FEV1  80% of the theoretical value and 
FEV1/FVC  70% in stable phase (Global Obstructive Lung 
Disease [GOLD] stage II or greater).25 Clinical stability was 
defined as the absence of symptoms of exacerbation in the 
6 weeks prior to inclusion. Patients who received antibiotic 
or steroid treatment for exacerbation in the 2 months previous 
to inclusion in the study were excluded, as were patients who 
had never smoked or had smoked less than 10 pack-years and 
those with bronchial asthma, cystic fibrosis, bronchiectasis 
not associated with COPD, alpha-1-antitrypsin deficiency, 
neoplasia, pneumonia, life expectancy of less than 2 years 
due to a severe concomitant disease, illiterate or unable to 
complete the SGRQ.
Procedures and data collection
Medication for stable COPD was left to the discretion of 
the attending physician. Patients were visited at the time 
of inclusion in the study (baseline, visit 1) and at 6-month 
intervals thereafter (visits 2, 3, and 4) until completion of the International Journal of COPD 2010:5 13
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2-year study period (final, visit 5). At baseline, after verifying 
that the patient met eligibility criteria, the following data 
were recorded: demographics, symptoms and the degree 
of dyspnea, respiratory risk factors, treatment in the stable 
phase and number and characteristics of the exacerbations 
in the previous year, as well as the treatment administered. 
Dyspnea was evaluated according to the Medical Research 
Council (MRC) scale26 (0 = no dyspnea; 1 = dyspnea on going 
up two flights or stairs; 2 = breathlessness on going up one 
flight of stairs; 3 = dyspnea when walking on a flat surface; 
4 = dyspnea at rest). A forced spirometry was performed 
unless the patient had undergone spirometry within the last 
6 months. Forced spirometry was repeated at the end of 
the study (visit 5).
At baseline and at each scheduled follow-up visit, patients 
completed the Spanish validated version of the SGRQ.27 
The SGRQ is a standardized self-administered airways dis-
ease-specific questionnaire that contains 50 items (covering 
76 levels) divided into three subscales: “Symptoms” (8 items), 
including several respiratory symptoms, their frequency and 
severity; “Activity” (16 items), concerned with activities 
that cause or are limited by breathlessness; and “Impacts” 
(26 items), which covers a range of aspects concerned with 
social functioning and psychological disturbances resulting 
from airway disease. A score ranging from 0 (no impairment 
or perfect state of health) to 100 (maximum impairment or 
worst possible state of health) is obtained. A score change 
of 4 points or more was considered clinically relevant in the 
health status of the patient.28 The SGRQ was completed by 
patients under the supervision of the investigators and in 
accordance with instructions of the manual.
Data of the five scheduled visits were recorded during a 
stable phase of the disease, that is, at least after one month 
of the last exacerbation episode. Patients were instructed 
to go to their physician on presentation of an exacerbation 
episode during the 2 years of the study. Exacerbations were 
defined in terms of increased dyspnea, sputum production, 
and sputum purulence that required a change in the patient’s 
regular treatment.29 In addition to bronchodilator and/or 
steroid treatment, if the patient was considered candidate 
to be treated with oral antibiotics at the judgment of the 
responsible physician, the preferably prescribed treat-
ment was a 5-day course of oral moxifloxacin, 400 mg 
once daily, or a 10-day course of amoxicillin/clavulanate, 
500/125 mg 3 times a day. Data on the exacerbation epi-
sode was recorded, and patients were appointed to the 
primary care center for a visit 7 to 10 days after starting 
antibiotic treatment to assess the outcome of the episode. 
The antibiotic regimen prescribed for the first exacerbation 
episode was maintained for all successive episodes through-
out the study period.
At each scheduled visit, information about episodes 
of exacerbation treated by the patients themselves with 
antibiotics and/or oral corticosteroids was obtained. These 
episodes were recorded as unreported exacerbations.
statistical analysis
A descriptive analysis of data was performed. Unpaired 
Student’s t test was used for comparison of independent data 
that followed a normal distribution. Non-normally distributed 
variables were compared by means of the Wilcoxon test. 
The Student’s t test for repeated measurements was used for 
paired data, if they followed a normal distribution. Otherwise, 
the Wilcoxon rank sum test was applied. The chi-square (χ2) 
test was used for the comparison of categorical variables. 
Statistical significance was set at P  0.05. The analysis 
was performed using SAS software (SAS Institute, Cary, 
SC, USA) version 9.1 for Windows.
Results
A total of 27 family physicians participated in the study and 
recruited 236 patients with stable COPD. Seven of these 
patients, however, did not meet the selection criteria and 
were not enrolled. Therefore, the study population included 
229 patients, 218 men and 11 women, with a mean (standard 
deviation, SD) age of 68.2 (10.2) years. Baseline character-
istics and HRQoL data of the study population have been 
described in a previous study.22 During the follow-up period, 
136 patients had at least one exacerbation and 124 (91.1%) 
patients received the study medications (amoxicillin/
clavulanate, n = 54; moxifloxacin, n = 70). Thirty-two (59.2%) 
patients in the amoxicillin/clavulanate group and 46 (65.7%) 
in the moxifloxacin group completed the study. The disposi-
tion of patients is shown in Table 1.
The mean (SD) FEV1 was 49.3% (15.3%) indicating 
moderate impairment of pulmonary function. COPD has 
been present for a mean of 11 (8.1 years). A total of 81.2% 
of patients presented other concomitant diseases especially 
hypertension, diabetes, chronic heart failure, and ischemic 
heart disease. Seventy-seven percent of patients had had 
acute exacerbation episodes in the previous year, with a 
mean of 1.6 (1.2) episodes and 15% were admitted to the 
hospital. The mean total score of the SGRQ was 40.7 (20.3). 
As shown in Table 2, patients who completed the study and 
those who did not showed comparable results of lung function 
tests, although a higher percentage of current smokers was International Journal of COPD 2010:5 14
Miravitlles et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
observed among those who discontinued the study, as well as 
higher values in total score and the “Activity” subscale and 
lower values in the “Symptoms” subscale of the SGRQ. On 
the other hand, there were no statistically significant differ-
ences in baseline parameters between moxifloxacin-treated 
and amoxicillin/clavulanate-treated patients, although those 
who did not complete the study scored higher in the total 
score, “Symptoms” and “Activity” subscales of the SGRQ 
(Table 3).
During the 2-year follow-up period a total of 386 exac-
erbations were recorded, of which 51 (13.2%) were unre-
ported to the investigators and detected only at scheduled 
visits. In the group treated with amoxicillin/clavulanate, 
24 patients (75%) had two or more exacerbations compared 
with 29 (63%) in the moxifloxacin group (P = 0.21). The 
mean number of episodes was 2.9 (2.2) in the moxifloxacin 
group vs 3.2 (3.0) in the amoxixillin/clavulanate group 
(P = 0.42). The time between the first and the second exacer-
bation was 198.38 (116.35) days among moxifloxacin-treated 
patients and 181.62 (154.56) days among those treated with 
amoxicillin/clavulanate; the differences were not statistically 
significant (P = 0.36).
A comparison of changes in SGRQ and respiratory 
function tests for the two groups of antimicrobial therapy is 
shown in Table 4. The change in SGRQ; that is the differences 
between scores at baseline and at the end of follow-up were 
significantly higher in the moxifloxacin group compared 
with amoxicillin/clavulanate for total SGRQ (-2.6 [13.1] vs 
4.2 [16.2], P = 0.05) and “Symptoms” subscale (-5.6 [16.7] vs 
8.3 [21], P = 0.02). On the other hand, statistically significant 
differences in favor of a higher effect on HRQoL for 
moxifloxacin compared with amoxicillin/clavulanate were 
also observed in the subsets of patients with two or more 
exacerbations for the total SGRQ (6.6 [17.5] vs -2.3 [15.1], 
P = 0.03) and “Symptoms” subscale (8.3 [23] vs –8.0 [16.8], 
P = 0.02) (Figure 1). No correlation was found between 
changes in lung function (FEV1) and total SGRQ scores 
(data not shown).
Compliance with antibiotic treatment was recorded in 
95.7% of cases. Both regimens showed a highly favorable 
tolerability profile with two patients treated with moxifloxa-
cin and four patients treated with amoxicillin/clavulanate 
presenting mild gastrointestinal complaints.
Discussion
The present study carried out to compare the long-term effect 
of treatment of acute exacerbations with moxifloxacin versus 
amoxicillin/clavulanate on the HRQoL of outpatients with 
COPD controlled in primary care showed a significantly 
higher beneficial impact of moxifloxacin on total scores of 
the SGRQ and the “symptoms” subscale than the standard 
regimen of amoxicillin/clavulanate. This favorable outcome 
was also observed in the subset of patents who had at least 
two episodes of acute exacerbation of COPD during the 
2-year study period. The length of time between the first and 
second exacerbation was about 16 days longer for the moxi-
floxacin group than for the amoxicillin/clavulanate group, 
but the differences were not significant probably because of 
the small sample size of the study. Therefore, it is likely that 
a better eradication rate with moxifloxacin would translate 
into a prolonged time to the next exacerbation. This effect 
was demonstrated in 355 patients with new exacerbations 
during the follow-up period in the MOSAIC trial.16 The mean 
time to event was 14 days longer with moxifloxacin treatment 
than comparators (amoxicillin, clarithromycin or cefuroxime-
axetil) and the difference was statistically significant.
These findings, together with a more advantageous dosage 
(400 mg orally once daily for 5 days), support the use of 
Table 1 Disposition of the study population
  Total Amoxicillin clavulanate Moxifloxacin No study medication
Patients recruited 236
    Inclusion criteria were not fulfilled 7
Patients enrolled 229 54 70 105
  Follow-up disposition
    Change of residence 3 4 7
       Voluntary withdrawal 1 1 2
      Death (not related to study medication) 4 2 8
      Failure to attend scheduled visits 14 17 30
    Total 22 24 47
Completed the study 136 32 46 58a
ano exacerbation episodes, n = 46; not treated with antibiotics, n = 8; treated with other antimicrobials, n = 4.International Journal of COPD 2010:5 15
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moxifloxacin as first-line therapy in bacterial exacerbations 
in patients with COPD and risk factors for treatment failure. 
The rationale for the prevention of exacerbations with moxi-
floxacin derives from a combination of at least three different 
factors: a) an immunomodulatory effect of the drug;30 b) the 
rapid and more complete eradications prevents epithelial 
damage and restores the local defence mechanisms of the 
bronchial mucosa;31 and c) as a result of the better eradica-
tion, fewer viable pathogens remain in the bronchial tissue 
after antimicrobial treatment, requiring a longer time for 
the bacterial population to increase sufficiently to induce 
a new exacerbation.32,33 On the other hand, the complete 
Table 2 Baseline characteristics of the study population
  
 
All patients  
(n = 229) 
Completed  
the study  
(n = 136)
Did not complete  
the study  
(n = 93)
P value 
 
sex, males 218 (95.2) 131 (96.3) 87 (93.6) 0.33
Age, years, mean (sD) 68.2 (10.2) 70 (9.7) 66.4 (10.4) 0.47
Active smoker 78 (34.2) 36 (26.5) 42 (45.7) 0.01
Pack-years 50.8 (28.3) 54.8 (30.9) 44.9 (22.8) 0.02
Duration of COPD, years, mean (sD) 11.1 (8.1) 11.7 (8.1) 10.1 (8.0) 0.08
Comorbidity 186 (81.2) 107 (78.7) 79 (84.9) 0.23
Chronic cough 195 (85.2) 109 (80.1) 86 (92.5) 0.01
expectoration 180 (78.6) 104 (76.5) 76 (81.7) 0.34
Dyspnea, grade
  0 or 1 114 (49.7) 73 (53.7) 41 (44.1) 0.19
  2 68 (29.7) 39 (28.7) 29 (31.2) 0.68
  3 or 4 47 (20.5) 24 (17.7) 23 (24.7) 0.19
Pulmonary function tests
  FVC, L 2.75 (0.82) 2.76 (0.77) 2.72 (0.90) 0.65
  FVC, % predicted 66.4 (16.5) 66.3 (15.6) 66.7 (18.1) 0.72
  FeV1, L 1.52 (0.55) 1.51 (0.52) 1.53 (0.60) 0.91
  FeV1, % predicted 49.3 (15.3) 48.7 (14.5) 50.3 (16.5) 0.51
  FeV1/FVC, % 54.8 (10.6) 54.4 (10.8) 55.4 (10.3) 0.52
gOLD stages: stage II 109 (49.3) 65 (48.5) 44 (47.8) 0.76
stage III 52 (23.5) 34 (25.4) 18 (19.5) 0.67
stage IV 60 (27.1) 35 (26.1) 25 (27.1) 0.81
exacerbations in the previous year 176 (77.2) 99 (73.3) 77 (82.8) 0.09
hospital admissions previous year 35 (15.4) 20 (14.8) 15 (16.1) 0.78
Treatment of COPD
  short-acting beta2 agonists 100 (43.7) 62 (45.6) 38 (40.9) 0.48
  Long-acting beta2 agonists 122 (53.3) 73 (53.7) 49 (52.7) 0.88
  Ipratropium bromide 139 (60.7) 82 (60.3) 57 (61.3) 0.88
  Inhaled steroids 120 (52.4) 79 (58.1) 41 (44.1) 0.04
  Theophyllines 37 (16.2) 22 (16.2) 15 (16.1) 0.99
  Mucolytic agents 15 (6.6) 6 (4.4) 9 (9.7) 0.11
SGRQ, mean (SD)
  Total score 40.7 (20.3) 39.6 (18.5) 48.7 (20.9) 0.03
  symptoms 49.0 (20.8) 47.8 (30.9) 50.8 (22.5) 0.01
  Impact 31.8 (21.8) 31.2 (20.5) 32.5 (23.7) 0.23
  Activity 51.6 (25.0) 49.6 (22.5) 54.4 (28.0) 0.01
Notes: Data expressed as number of patients and percentages in parentheses unless otherwise stated.
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; sgRQ, st. george’s Respiratory 
Questionnaire.International Journal of COPD 2010:5 16
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eradication of bacteria present in the airways is important for 
the prevention of resistance development.18,34
Patients with COPD experience impairment in daily life 
activities35 and, additionally, exacerbations may have a long-
term effect on their HRQoL.20 Spencer and Jones19 showed 
that the effect of exacerbations on HRQoL may persist for 
months. However, the greatest improvement in SGRQ scores 
takes place during the first month after the episode. To avoid 
interference of the last exacerbation with the SGRQ scores, 
measurements were obtained at least one month after the 
last exacerbation and during periods of clinical stability. 
The observation that patients with frequent exacerbations 
have worse SGRQ scores than patients with infrequent 
exacerbations21 was also confirmed in our study.24 In this 
Table 3 Baseline characteristics of the patients who completed the 2-year follow-up according to treatment group
   Amoxicillin/clavulanate  
(n = 32)
Moxifloxacin  
(n = 46)
P value 
sex, males 32 (100) 43 (93.4) 0.14
Age, years, mean (sD) 66.3 (10.2) 70 (9.1) 0.17
Active smoker 9 (28.1) 4 (8.7) 0.02
Pack-years 56.8 (27.3) 52.6 (35.9) 0.18
Duration of COPD, years, mean (sD) 11.3 (9.8) 13.6 (7.6) 0.06
Comorbidity 29 (90.6) 34 (73.9) 0.06
Chronic cough 24 (75) 34 (73.9) 0.91
expectoration 23 (71.9) 32 (69.6) 0.82
Dyspnea, grade
  0 or 1 21 (65.5) 21 (45.6) 0.23
  2 7 (21.8) 19 (41.3) 0.07
  3 or 4 4 (11.4) 6 (13) nA
Pulmonary function tests
  FVC, L 2.68 (0.68) 2.61 (0.77) 0.53
  FVC, % predicted 63.2 (13.9) 64.8 (15.5) 0.74
  FeV1, L 1.53 (0.51) 1.41 (0.53) 0.27
  FeV1, % predicted 48.3 (14.6) 47.7 (15.6) 0.83
  FeV1/FVC, % 56.7 (11.2) 53.5 (10.4) 0.10
gOLD stages: stage II 16 (50.0) 21 (45.6) 0.70
stage III 5 (15.7) 12 (26.1) 0.27
stage IV 10 (31.3) 13 (28.3) 0.77
exacerbations in the previous year 25 (78.1) 37 (80.4) 0.80
hospital admissions previous year 6 (18.8) 8 (17.4) 0.91
Treatment of COPD
  short-acting beta2 agonists 11 (34.4) 21 (45.7) 0.32
  Long-acting beta2 agonists 20 (62.5) 31 (67.4) 0.65
  Ipratropium bromide 23 (71.9) 28 (60.9) 0.31
  Inhaled steroids 17 (53.1) 35 (76.1) 0.03
  Theophyllines 9 (28.1) 6 (13) 0.09
  Mucolytic agents 4 (8.7) 0 (0) 0.08
SGRQ, mean (SD)
  Total score 37 (14.7) 44.8 (19.4) 0.06
  symptoms 44.9 (18.2) 52.9 (17.7) 0.10
  Impact 28.6 (15.8) 38.1 (22.1) 0.06
  Activity 47.6 (20.8) 51.9 (23.2) 0.16
Notes: Data expressed as number of patients and percentages in parentheses unless otherwise stated. 
Abbreviations: nA, not applicable; COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; sgRQ, st george’s 
Respiratory Questionnaire.International Journal of COPD 2010:5 17
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Table 4 Changes in the sgRQ and respiratory function test according to the antibiotic treatment prescribed and exacerbation 
episodes
SGRQ scores FEV1, mL  FEV1 %
  Total Symptoms Activity Impacts
Amoxicillin/clavulanate, n = 32
    Baseline 37.0 (14.7) 44.1 (18.2) 47.5 (20.8) 29.5 (15.1) 1.53 (0.5) 48.3 (14.6)
    Final visit 41.2 (17.3) 52.3 (21.8) 53.3 (22.4) 31.7 (17) 1.56 (0.6) 51.4 (17.9)
    Difference 4.2 (16.2) 8.3 (21) 5.7 (21.6) 2.2 0.03 (0.4) 3.06 (14.3)
One exacerbation, n = 8
    Baseline 41.8 (15.4) 50.6 (19.4) 51.1 (19.1) 33.5 (18.2) 1.75 (0.4) 54.9 (11.2)
    Final visit 38.8 (14.1) 55.6 (15.9) 45.9 (22.8) 29.2 (13.5) 1.71 (0.5) 54.3 (15.5)
    Difference –3.0 (9) 5.0 (14.8) –5.2 (11.1) –4.3 (15) –0.04 (0.4) –0.6 (11.1)
Two or more exacerbations, n = 24
    Baseline 35.4 (14.5) 43.0 (17.8) 46.4 (21.6) 28.1 (14.1) 1.45 (0.5) 46.0 (15.2)
    Final visit 42.0 (18.5) 51.3 (23.6) 55.8 (22.3) 32.6 (18.1) 1.52 (0.6) 50.4 (18.9)
    Difference 6.6 (17.5) 8.3 (23) 9.4 (23.4) 4.5 (19.3) 0.07 (0.5) 4.4 (15.3)
Moxifloxacin, n = 46
    Baseline 44.8 (19.3) 52.9 (17.7) 54.3 (20.8) 39.0 (21.5) 1.41 (0.5) 47.8 (15.7)
    Final visit 42.2 (19.2) 47.3 (16.4) 56.1 (22) 36.2 (21.1) 1.49 (0.5) 52.8 (18.2)
    Difference –2.6 (13.1) –5.6 (16.7) 1.8 (15.4) –2.8 (16.9) 0.08 (0.37) 5.0 (17.8)
One exacerbation, n = 17
    Baseline 39.3 (23.2) 45.1 (18.8) 49.8 (26.5) 37.2 (23.3) 1.46 (0.6) 49.8 (15.1)
    Final visit 36.1 (21.9) 43.6 (13.6) 50.8 (28.1) 31.2 (25) 1.61 (0.6) 57.9 (21.7)
    Difference –3.2 (9.2) –1.5 (16) 1.0 (15.2) –6.0 (12.3) 0.15 (0.5) 8.1 (17.8)
Two or more exacerbations, n = 29
    Baseline 48.0 (16.4) 57.5 (15.5) 56.6 (17.2) 40.0 (20.9) 1.38 (0.5) 46.6 (16.1)
    Final visit 45.7 (16.7) 49.5 (17.7) 58.8 (17.9) 39.0 (18.4) 1.42 (0.4) 49.8 (15.5)
    Difference –2.3 (15.1) –8.0 (16.8) 2.2 (15.8) –1.00 (19.1) 0.04 (0.3) 3.2 (8.9)
Abbreviations: FeV1, forced expiratory volume in 1 second; sgRQ, st george’s Respiratory Questionnaire.
All
P = 0.05
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Figure 1 Differences in the total score of the st george’s Respiratory Questionnaire 
(sgRQ) according to antibiotic treatment in the whole study population, in patients 
with one exacerbation of COPD and in those with more than one exacerbation. 
standard deviation in parentheses.
respect, the accumulation of episodes of acute exacerbation 
has an impact on the health status in the long term.19–21
The present results should be interpreted taking into 
account some limitations of the study, such as the relatively 
small number of patients treated with study medications 
that completed the study (46 in the moxifloxacin group and 
32 in the amoxicillin/clavulanate group). Nonetheless, we 
observed significant differences in the impact of exacerba-
tions on HRQoL according to the different antimicrobial 
treatment. These differences were increased in patients 
with frequent exacerbations. Those treated with moxifloxa-
cin had a small nonclinically significant improvement of 
2.24 units compared with an impairment of 6.60 units of 
patients with frequent exacerbations treated with amoxi-
cillin/clavulanate, with this change being higher than the 
4 units considered to be the clinically relevant change in 
the SGRQ.28International Journal of COPD 2010:5 18
Miravitlles et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Although most demographics, clinical data, and results 
of respiratory function tests at baseline were similar for 
those who completed the study and received antibiotics than 
for those who did not complete the study, those lost during 
follow-up were less likely to be active smokers, complain 
of chronic cough and use inhaled corticosteroids, and 
also reported a lower tobacco consumption. Patients who 
withdrew from the study also scored higher in total score, 
“Symptoms” and “Activity” subscales of the SGRQ. This 
may indicate a higher impact of COPD on HRQoL in those 
patients who did no complete the 2-year study period. These 
differences should not influence the comparison between the 
impact of the two antibiotics on the changes in SGRQ scores 
over time. As far as we are aware, no previous study has been 
carried out to assess the long-term effect of two different 
antibiotic regimens for the treatment of exacerbation using 
HRQoL as the outcome measure. The effect of exacerbations 
on the HRQoL of patients with COPD has been demonstrated 
in previous studies18,20,21 but in none were the SGRQ scores 
used to determine the impact of treatment of COPD exac-
erbations with antimicrobials. In addition, the present study 
was performed in a nonclinical trial setting in ambulatory 
patients with COPD attended in primary care centers, which 
enhances the external validity of the study.
We conclude that in outpatients with moderate COPD 
controlled by primary care physicians during a 2-year period, 
treatment of acute exacerbation episodes with a 5-day course 
of moxifloxacin (400 mg once daily) had a more favorable 
effect on health-related quality of life than the standard 
10-day course of amoxicillin/clavulanate (500/125 mg 
three times a day). Differences were observed between the 
two antibiotic regimens for both the total SGRQ score and 
the “Symptoms” domain. Health-related quality of life, 
particularly using disease-specific instruments such as 
SGRQ, should be included in the broad range of endpoints 
when assessing the long term outcome of exacerbation 
treatment of COPD.
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